Repeat Dose Study in Male Healthy Volunteer Smokers

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00615576
First received: February 1, 2008
Last updated: October 14, 2010
Last verified: October 2010
  Purpose

This is a 4 to 6 week study to look at the safety and PK profile of SB656933 in healthy male smokers


Condition Intervention Phase
Chronic Obstructive Pulmonary Disease (COPD)
Cystic Fibrosis
Drug: SB656933
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SB-656933 Following 14 Days Repeat Dosing in Healthy Male Smokers.

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • -what the body does to the drug over a 17 day of dosing with 100mg of SB656933. -Safety of SB-656933: Adverse events, blood pressure, heart rate, electrocardiogram, epididymal ultrasound and lab tests [ Time Frame: 17 days ]
  • -what the body does to the drug over a 17 day of dosing with 100mg of SB656933 by taking PK samples at: [ Time Frame: pre-dose and at 0.5,1,2,3,4,6,8,12 and 24 hours post-dose on days 1 and 14; pre-dose on Day7. Additional samples at 32, 48 and 72 hours post-dose wil ]
  • -Safety of SB-656933: Adverse events every day for entire study period: blood pressure , heart rate and temperature [ Time Frame: taken pre-dose, 30min, 1hr, and 2hr on Day1, Day2, Day7 and Day14 (supine only); ]
  • electrocardiogram [ Time Frame: pre-dose, 2hr and 4 hr on Day1 ]

Secondary Outcome Measures:
  • - Looking at the actual sample size data to determine a larger theoretical population. -What the drug does to the body when present at its lowest level on day 14 as compared before drug given. [ Time Frame: 17 days ]
  • Safety and tolerability of SB-656933 in subjects with cystic fibrosis, including adverse events, vital signs, clinical laboratory assessments, electrocardiographic (ECG) parameters, and lung function (FVC, FEV1)
  • Fluorocytometric quantitation of CXCL1-induced CD11b expression on peripheral blood neutrophils in ex-vivo assay.
  • Neutrophil shape change in response to stimulation with CXCL-1 in whole blood ex-vivo gated autofluorescence forward scatter (GAFS) assay.
  • Looking at the actual sample size data to determine a larger theoretical population.
  • What the drug does to the body when present at its lowest level on day 14 as compared before drug given. [ Time Frame: on day 14 ]

Estimated Enrollment: 16
Study Start Date: March 2008
Study Completion Date: July 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: SB656933
    Other Name: SB656933
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy adult male smokers who are between 18-65 years of age with normal genitourinary anatomy based on physical examination.
  • The subjects should have a normal colour Doppler epididymal ultrasound (normal blood flow and epididymal morphology) at screening.
  • The first 10 mL of urine voided (VB1) should be normal at screening and pre-dose.
  • Male subjects must agree to abstain from or use a condom during sexual intercourse with pregnant females; or use a condom/spermicide, in addition to having their female partner use another form of contraception, such as an IUD, diaphragm with spermicide, oral contraceptives, injectable progesterone, subdermal implants or a tubal ligation, if engaging in sexual intercourse with a female partner who could become pregnant. This criterion must be followed from the time of the first dose of study medication until 84 days after the last dose of study medication.
  • The subject has a QTc(B) <450msec at screening or prior to dosing
  • Body weight = 50 kg (110 pounds) and body mass index (BMI) between 19 and 30 inclusive where: BMI =weight in kg/(height in meters)2
  • Healthy male smokers must smoke more than 10 cigarettes per day, for at least 2 months prior to screening and less than 30 cigarettes per day at the time of enrolment.
  • Subjects with Forced Expiratory Volume (FEV1)=80% predicted and FEV1/Forced Vital Capacity (FVC) ratio=0.7.
  • Signed and dated written informed consent prior to admission to the study
  • The subject is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.

Exclusion Criteria:

  • Any clinically relevant abnormality identified on the screening medical assessment, laboratory examination, or 12-lead ECG.
  • The subject has liver function tests (LFT) elevated above the reference range at pre-study screening that remain elevated with a repeat LFT (to be discussed with the sponsor, if necessary).
  • Subjects with absolute neutrophil count (ANC) = 2.0x109/L.
  • Subjects who have previously been exposed to testicular radiotherapy.
  • Subjects who have had previous testicular or prostate surgery including vasectomy.
  • History of prostatitis, epididymitis, epididymal cysts, structural abnormalities or testicular cancer.
  • Subjects with abnormalities of the renal tract, renal stones or history of Urinary Tract Infections (UTI's).
  • Positive drug or alcohol test at screening or prior to dosing.
  • Positive HIV, Hepatitis B surface antigen or Hepatitis C antibody at screening
  • Use of prescription or non-prescription medication in the last 7 days or 5 half-lives (whichever is longer) , particularly drugs that are P450 CYP3A4, CYP2B6, CYP2C8 or OATP1B1 substrates with a narrow therapeutic index , and including vitamins and herbal remedies such as St John's Wort prior to dose of study medication.
  • Consumption of grapefruit or grapefruit juice within seven days prior to the first dose of study medication.
  • Donation of blood in excess of 500 mL within a 56 day period prior to dosing.
  • Exposure to more than 3 new chemical entities within 12 months prior to the first dosing day.
  • Participation in a trial with any drug within 3 months before the start of the study or participation in a trial with a new chemical entity within 4 months before the start of the study.
  • Are receiving treatment for smoking cessation.
  • Are using tobacco products other than cigarettes (e.g. pipes, cigars, snuff, chewing tobacco).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00615576

Locations
United Kingdom
GSK Investigational Site
London, United Kingdom, NW10 7NS
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials, MD GlaxoSmithKline
  More Information

No publications provided

Responsible Party: Study Director, GSK
ClinicalTrials.gov Identifier: NCT00615576     History of Changes
Other Study ID Numbers: CR2111256
Study First Received: February 1, 2008
Last Updated: October 14, 2010
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by GlaxoSmithKline:
Male,
Healthy Volunteer,
Smoker,
Cystic Fibrosis,
Chronic Obstructive Lung Disease

Additional relevant MeSH terms:
Cystic Fibrosis
Fibrosis
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Digestive System Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Pancreatic Diseases
Pathologic Processes
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on October 21, 2014